In the case of ovarian carcinoma and multiple myeloma cells, the enhancement of TP53 expression was also demonstrated against the background of the antitumor effect of different GnRH-I agonists and antagonists [30,55]. This evidence concerns the gene TP53 and ovarian carcinoma.